XXII Achieves “Holy Grail” of Cannabis Plant Science 22nd Century Group (XXII) just announced a breakthrough in its hemp/cannabis plant research leading to the successful transformation of the hemp/cannabis plant genome using a proprietary plant...
Lexaria Bioscience Pursuing Regulatory Approvals for DehydraTECH CBD Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. Related: Should You...
Lexaria Bioscience CBD Study Results Expected to Demonstrate Effectiveness Against Hypertension Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete...
Should you buy this cannabis biotech stock CURE Pharmaceutical? CURE Pharmaceutical Holding Corp. (OTC: CURR) focuses on the development and manufacturing of drug formulation and drug delivery technologies in novel dosage forms (thin wafers and thin films). Notably,...
Psychedelic Stocks: Nova Mentis Files Genetic Disease Patent Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based...
Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent — McMaster University researchers using MediPharm Labs’ CBD50 formula and a CBD:THC 10:2 formulation, which has the same cannabinoid ratio as MediPharm...